Blog

Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma

Samer Al Hadidi/LinkedIn

Mar 18, 2025, 10:01

Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma

Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, posted on LinkedIn about recent paper he and colleagues co-authored, titled “Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma” published on American Society of Hematology Blood Advances.

Authors: Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D. Shaughnessy, Jr, Fenghuang Zhan, Eric R. Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

“Check out recent work published American Society of Hematology Blood Advances.

Prior Exposure to Belantamab, Mafodotin Influences Outcomes with Idecabtagene ,Vicluecel in Patients with Multiple Myeloma.”

American Society of Hematology Blood Advances Bhavesh Mohan Lal cancer Carolina Schinke Eric R. Siegel Fenghuang Zhan Frits Van Rhee Jawad Alrawabdeh John D. Shaughnessy Jr Marah Alzubi Maurizio Zangari multiple myeloma OncoDaily Oncology Samer Al Hadidi Sharmilan Thanendrarajan

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action